---
title: "Obefazimod (ABX464) in Ulcerative colitis: Effects on other drugs"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Effects on other drugs. Topics: Caffeine, a CYP1A2 substrate: caffeine exposure with single and repeated obefazimod doses (Part A); Caffeine: design of the inhibition and induction assessments; Caffeine: sponsor plain-language summary of results; Rosuvastatin: phase 1 interaction study in healthy men; 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/effects-on-other-drugs"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Effects on other drugs

<a id="heading-2.1.2.9.2"></a>

## 2.1.2.9.2 Effects of Obefazimod on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

### Caffeine, a CYP1A2 substrate: caffeine exposure with single and repeated obefazimod doses (Part A)

| Parameter | Day 1, caffeine 50 mg alone | Day 4, caffeine with obefazimod 50 mg | Day 17, caffeine with obefazimod after 14 days of daily dosing |
| --- | --- | --- | --- |
| Participants analyzed | “22” | “22” | “22” |
| Caffeine Cmax, ng/mL, mean (SD) | “931(285)” | “930(278)” | “564(242)” |
| Caffeine AUC, h*ng/mL, mean (SD) | “7420(4760)” | “5460(2740)” | “1560(719)” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-2.1.2.9.2-2"></a>

### Caffeine: design of the inhibition and induction assessments

> “Caffeine is administered on Day 1 in the absence of ABX464, on Day 4 simultaneously with ABX464 to evaluate potential CYP1A2 inhibition by ABX464, and on Day 17 simultaneously with ABX464 following 14 days of once daily dosing of ABX464 to evaluate potential CYP1A2 induction by ABX464.”
> “Of the 24 participants enrolled into Part A of the study, 2 participants were excluded from the PK analysis set due to meeting PK exclusion set criteria for non-adherence with pre-dose caffeine restrictions.”

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-2.1.2.9.2-3"></a>

### Caffeine: sponsor plain-language summary of results

> “ABX464 does not demonstrate any drug-drug interactions for drugs which are broken down (metabolised) by the enzyme CYP1A2 as the levels of caffeine and fluvoxamine in the blood remained similar in both the presence and absence of ABX464.”

Source: [Health Research Authority research summary, ABX464 drug-drug interaction study](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-2-part-drug-drug-interaction-study-of-abx464-in-healthy-volunteers)

<a id="topic-2.1.2.9.2-4"></a>

### Rosuvastatin: phase 1 interaction study in healthy men

> “A Phase 1, 2-part, open-label, single-sequence study to investigate the effect of single and multiple doses of obefazimod on the pharmacokinetics of rosuvastatin in healthy male participants.”
> “Summary of the results: deferred: adult category 1 trial (mostly phase I), results to be published from 20 Aug 2027 (EMA/263067/2023).”

Source: [CTIS.eu 2023-509226-21-00](https://ctis.eu/trial/2023-509226-21-00)

<a id="topic-2.1.2.9.2-5"></a>

### Combined oral contraceptive (ethinyl estradiol and drospirenone): phase 1 interaction study in healthy women

> “A study to investigate the effects of multiple doses of obefazimod on a combined oral contraceptive (ethinyl estradiol/drospirenone) in healthy female participants of childbearing potential.”
> “Summary of the results: deferred: adult category 1 trial (mostly phase I), results to be published from 28 Feb 2027 (EMA/263067/2023).”

Source: [CTIS.eu 2023-505297-15-00](https://ctis.eu/trial/2023-505297-15-00)

<a id="topic-2.1.2.9.2-6"></a>

### Completed interaction studies supporting the planned NDA

> “(i) two drug-drug interaction trials, for the purposes of providing further information on any possible interactions of obefazimod with other drugs, for which we enrolled 24 and 36 healthy volunteers respectively;”
> “The results of these Phase 1 clinical trials provide supportive data for our further clinical development and New Drug Application”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

Additional sources: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
